ADIA · XBRL financial data
Adia Nutrition financial statements, every quarter
The same tables from 3 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (ADIA's year ends in late December)
| In thousands of dollars | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|
| Revenue | year only | 176 | 485 |
| Cost of revenue | year only | 109 | 203 |
| Gross profit | year only | 68 | 283 |
| Research and development | year only | — | 0 |
| General and administrative | year only | 182 | 208* |
| Total operating expenses | year only | 219 | 231 |
| Operating income (loss) | year only | (152) | 52 |
| Interest expense | year only | 11 | 12 |
| Income tax expense (benefit) | year only | 0 | 0 |
| Net income (loss) | year only | (163) | 40 |
| Earnings per share, basic USD per share | — | 0.00 | 0.00 |
| Earnings per share, diluted USD per share | — | 0.00 | 0.00 |
| Weighted average shares, basic thousands of shares | — | 94,405 | 94,405 |
| Weighted average shares, diluted thousands of shares | — | 94,405 | 161,405 |
Balance sheet
CSVFiscal quarters (ADIA's year ends in late December)
| In thousands of dollars | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|
| Cash and cash equivalents | 79 | 137 | 128 |
| Accounts receivable | 33 | 79 | 44 |
| Inventory | 25 | — | — |
| Total current assets | 162 | 359 | 343 |
| Property and equipment, net | 31 | 35 | 33 |
| Right-of-use asset | 108 | 94 | 80 |
| Total assets | 595 | 777 | 744 |
| Accounts payable | 2 | 28 | 5 |
| Total current liabilities | 145 | 1,110 | 1,057 |
| Lease liability, non-current | 46 | 32 | 17 |
| Total liabilities | 853 | 1,197 | 1,124 |
| Accumulated deficit | (15,973) | (16,136) | (16,096) |
| Total stockholders' equity | (258) | (420) | (380) |
| Total liabilities and equity | 595 | 777 | 744 |
| Common shares outstanding (cover page) thousands of shares | 94,405 | 94,405 | 94,405 |
Cash flows
CSVFiscal quarters (ADIA's year ends in late December)
| In thousands of dollars | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 |
|---|---|---|---|
| Net income (loss) | year only | (163) | 40 |
| Stock-based compensation | year only | 0 | 0 |
| Depreciation and amortization | year only | 1 | 1* |
| Net cash from operating activities | year only | (55) | (109)* |
| Purchases of property and equipment | year only | 5 | 0* |
| Net cash from investing activities | year only | (5) | (5)* |
| Proceeds from issuing common stock | year only | — | — |
| Net cash from financing activities | year only | 118 | 106* |
| Net change in cash | year only | 57 | (9)* |
Compare with peers
SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Adia Nutrition | 128 | 485 | (109)* | 94.4M | 1.2 quarters | 10-QJun 30, 2026 |
| Silo Pharma | 3,277 | 0* | (782)* | 1.6M | 6.7 quarters | 10-QJun 30, 2026 |
| Skinvisible | 4 | 5 | 2.2* | 5.4M | — | 10-QJun 30, 2026 |
| Xenetic Biosciences | 6,472 | 661 | (875)* | 2.3M | 7.4 quarters | 10-QJun 30, 2026 |
| LFTD Partners | 1,504 | 8,705 | (555)* | 14.8M | 2.7 quarters | 10-QJun 30, 2026 |
| Natural Alternatives International | 7,388 | not reported | (1,066)* | 22.1M | 6.9 quarters | 10-KJun 30, 2026 |
| PharmaCyte Biotech | 17,739 | 0 | (781) | 10.7M | 22.8 quarters | 10-QJul 31, 2026 |
| Vyome Holdings | 7,888 | 27 | (904)* | 7.0M | 8.7 quarters | 10-QJun 30, 2026 |
| AIM ImmunoTech | 9,900 | 26 | (4,590)* | 30.4M | 2.2 quarters | 10-QJun 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.